Bayer inks deal to buy Ac-225 from BWXT Medical

By staff writers

June 27, 2022 -- Bayer has signed a deal to buy the radioisotope actinium-225 (Ac-225) at predetermined prices from BWXT Medical, a subsidiary of BWX Technologies.

The two companies expect supply to commence later this year. This announcement builds upon an agreement reached by the two companies in September 2021.

Ac-225 is used in targeted alpha therapies (TATs). This emerging field combines Ac-225 with specific tumor-seeking targeting moieties that deliver alpha radiation directly to tumors.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking